We prioritized MAP2K1, TUBB3, FLNC, and ABCA1 because they harbored high-confidence, tumor-specific variants that passed our multi-tool pathogenicity prioritization and were among the most significantly dysregulated genes in the bulk transcriptome (with scRNA-seq support), nominating them as convergent genomic–transcriptional candidates for follow-up. The gene discussed is MAP2K1; the disease is neoplasm.